ACRS
Aclaris Therapeutics, Inc.
$6.41
+1.26%
2026-08-21
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Key Fundamentals
Forward P/E
-7.12
EPS (TTM)
$-0.58
ROE
-59.1%
Revenue Growth (YoY)
-8.3%
Profit Margin
0.0%
Debt/Equity
1.49
Price/Book
6.49
Beta
0.78
Market Cap
$850.8M
Avg Volume (10D)
2.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$6.51
60D Low
$4.08
Avg Volume
1.9M
Latest Close
$6.41
Get breakout alerts for ACRS
Sign up for Breakout Scanner to receive daily notifications when ACRS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Aclaris Therapeutics, Inc. (ACRS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ACRS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ACRS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.